Sodium nitroprusside injection and preparation method thereof

By adding mannitol, β-cyclodextrin and pH regulator to sodium nitroprusside injection, the pH value and low-temperature liquid preparation were controlled, the photosensitivity and thermal instability of sodium nitroprusside injection were solved, and injection was achieved High stability and safety of liquid.

CN119033682APending Publication Date: 2024-11-29HAINAN PULIN PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411150556.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Sodium nitroprusside injection has problems with photosensitivity and thermal instability, which leads to easy decomposition during preparation and storage, affecting product quality.

Method used

Injection consisting of sodium nitroprusside, mannitol, β-cyclodextrin and pH regulator (such as citric acid), by controlling the pH value between 4.5-5.5, combined with low-temperature liquid preparation (no more than 25℃) and microporous filtration Membrane filtration improves the light and thermal stability of sodium nitroprusside injection.

Benefits of technology

The photostability and thermal stability of sodium nitroprusside injection are significantly improved, ensuring the safety of the drug and long-term storage stability, and avoiding decomposition and precipitation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005003538410000041
    Figure BDA0005003538410000041
  • Figure BDA0005003538410000051
    Figure BDA0005003538410000051
  • Figure BDA0005003538410000052
    Figure BDA0005003538410000052
Patent Text Reader

Abstract

The invention relates to the technical field of pharmaceutical preparations, in particular to a sodium nitroprusside injection and a preparation method thereof. The sodium nitroprusside injection comprises sodium nitroprusside, mannitol, beta-cyclodextrin, a pH regulator and water for injection, wherein the pH regulator enables the pH value of the injection to be 4.5-5.5. Compared with the prior art, the sodium nitroprusside injection disclosed by the invention is simple in preparation method and good in stability, the problem of poor light stability of a sodium nitroprusside aqueous solution is solved, and the medication safety is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a sodium nitroprusside injection and a preparation method thereof. Background Art

[0002] Sodium Nitroprusside (SNP) is a fast-acting and short-acting vasodilator that has a direct dilating effect on arterial and venous smooth muscles. It reduces peripheral vascular resistance by dilating blood vessels and produces a hypotensive effect. The vasodilation effect can also reduce the preload and afterload of the heart, improve cardiac output, and reduce blood reflux during valvular insufficiency, thereby relieving the symptoms of heart failure. Currently, sodium nitroprusside is widely used to treat hypertensive emergencies and acute heart failure, and can also be used to control intraoperative bleeding and hypertension caused by aortic surgery, pheochromocytoma surgery, and cardiac surgery.

[0003] Sodium nitroprusside is thermally unstable and highly photosensitive. Sodium nitroprusside injection is easily decomposed by light during preparation or storage, causing iron ions to become ferrous ions, resulting in a decrease in pH and discoloration of the sodium nitroprusside solution. It is easy to produce turbidity or precipitation due to high-temperature decomposition, making the product fail to meet quality standards. Although sodium nitroprusside freeze-dried powder injection improves the storage stability of the drug, it has problems such as long preparation process cycle, high energy consumption and inconvenience in use. People still hope to convert sodium nitroprusside powder injection into injection.

[0004] Patent CN117731607A provides a sodium nitroprusside injection, which is prepared under the irradiation of a red light source. Disodium EDTA or sodium acetate is used as a stabilizer during the preparation process and the pH of the resulting solution is controlled, which effectively solves the light stability problem of sodium nitroprusside injection during the production process. However, the injection still has the risk of degradation during long-term storage.

[0005] Patent CN1857307A provides a sodium nitroprusside injection composed of an alcoholic medicinal solvent, a light stabilizer, a metal chelating agent, a pH adjuster, etc. The injection contains a large amount of alcoholic medicinal solvents. The alcoholic medicinal solvents have strong vascular irritation and are likely to cause pain at the injection site when injected into the blood vessels.

[0006] Therefore, there is still a need to develop a sodium nitroprusside injection with good stability and a preparation method thereof. Summary of the invention

[0007] In order to solve the above technical problems, the present invention provides a sodium nitroprusside injection and a preparation method thereof, which solves the problem of poor stability of sodium nitroprusside.

[0008] The present invention provides a sodium nitroprusside injection on one hand, which comprises the following raw materials: sodium nitroprusside, mannitol, beta-cyclodextrin, a pH regulator and water for injection.

[0009] The pH regulator of the present invention makes the pH value of the injection solution be 4.5-5.5.

[0010] The pH regulator of the present invention is selected from one or more of malic acid, fumaric acid, citric acid, tartaric acid, maleic acid and succinic acid.

[0011] Preferably, the pH regulator of the present invention is citric acid.

[0012] Preferably, each 1000 mL of the sodium nitroprusside injection of the present invention contains 25 g of sodium nitroprusside, 6-10 g of mannitol, and 25-45 g of β-cyclodextrin.

[0013] Further preferably, each 1000 mL of the injection of the present invention contains 25 g of sodium nitroprusside, 8 g of mannitol, and 30 g of β-cyclodextrin.

[0014] More preferably, each 1000 mL of the injection of the present invention contains 25 g of sodium nitroprusside, 8 g of mannitol, 30 g of β-cyclodextrin and an appropriate amount of citric acid, and the amount of citric acid makes the pH value of the injection be 4.5-5.5.

[0015] Another aspect of the present invention provides a method for preparing the sodium nitroprusside injection, the method comprising the following steps:

[0016] Step 1: Weigh an appropriate amount of water for injection, add the prescribed amount of β-cyclodextrin and mannitol, and stir to dissolve to obtain solution 1;

[0017] Step 2: Add the prescribed amount of sodium nitroprusside to solution 1, and stir to dissolve to obtain solution 2;

[0018] Step 3: Adjust the pH value of solution 2, add the remaining amount of water for injection to make up the volume, filter and sterilize with a microporous filter membrane, and fill to obtain the finished product.

[0019] The liquid preparation temperature during the preparation method of the present invention does not exceed 25°C, and the liquid preparation temperature can be 20°C±5°C.

[0020] The appropriate amount of water for injection in step 1 of the preparation method of the present invention is 70-90% of the prescribed amount of water for injection, preferably 80%.

[0021] The pH in step 3 of the preparation method of the present invention is adjusted to 4.5-5.5, and the pH adjuster is selected from one or more of malic acid, fumaric acid, citric acid, tartaric acid, maleic acid, and succinic acid, preferably citric acid.

[0022] The pore size of the microporous filter membrane in step 3 of the preparation method of the present invention is 0.45 μm or 0.22 μm.

[0023] The filling specification in step 3 of the preparation method of the present invention is 2 mL / bottle.

[0024] The beneficial effects of the present invention are as follows: the preparation method of the sodium nitroprusside injection of the present invention is simple, and the synergistic effect of the raw materials is fully exerted by compounding sodium nitroprusside, beta-cyclodextrin and mannitol, thereby improving the light stability and thermal stability of the sodium nitroprusside aqueous solution and ensuring the safety of the drug. DETAILED DESCRIPTION

[0025] In order to better understand the technical solution of the present invention, the technical solution of the present invention is further described below in conjunction with specific embodiments. The embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0026] Example 1

[0027] Prescription (based on 1000mL): Sodium nitroprusside 25g, mannitol 8g, β-cyclodextrin 25g, and appropriate amount of citric acid.

[0028] Preparation method:

[0029] (1) Weigh 80% of the prescribed amount of water for injection, add the prescribed amount of β-cyclodextrin and mannitol, and stir to dissolve to obtain solution 1;

[0030] (2) adding a prescribed amount of sodium nitroprusside to solution 1, stirring and dissolving to obtain solution 2, and maintaining the temperature at 20° C. during the preparation process;

[0031] (3) Add an appropriate amount of citric acid to adjust the pH of solution 2 to about 5.0, add the remaining amount of water for injection to make up the volume, filter and sterilize with a 0.22 μm microporous filter membrane, and fill into brown sterile penicillin bottles at a specification of 2 mL / bottle to obtain sodium nitroprusside injection.

[0032] Example 2

[0033] Prescription (based on 1000mL): Sodium nitroprusside 25g, mannitol 8g, β-cyclodextrin 45g, and appropriate amount of citric acid.

[0034] Preparation method: The amount of β-cyclodextrin is adjusted to 45 g, and the rest of the process is the same as Example 1.

[0035] Example 3

[0036] Prescription (based on 1000mL): Sodium nitroprusside 25g, mannitol 8g, β-cyclodextrin 30g, and appropriate amount of citric acid.

[0037] Preparation method: The amount of β-cyclodextrin is adjusted to 30g, and the rest of the process is the same as in Example 1

[0038] Example 4

[0039] Prescription (based on 1000mL): Sodium nitroprusside 25g, mannitol 6g, β-cyclodextrin 30g, and appropriate amount of citric acid.

[0040] Preparation method: The amount of β-cyclodextrin is adjusted to 30 g, the amount of mannitol is adjusted to 6 g, and the rest of the process is the same as Example 1.

[0041] Example 5

[0042] Prescription (based on 1000mL): Sodium nitroprusside 25g, mannitol 10g, β-cyclodextrin 30g, and appropriate amount of citric acid.

[0043] Preparation method: The amount of β-cyclodextrin is adjusted to 30 g, the amount of mannitol is adjusted to 10 g, and the rest of the process is the same as Example 1.

[0044] Comparative Example 1

[0045] Prescription (based on 1000mL): 25g sodium nitroprusside, 8g mannitol, and appropriate amount of citric acid.

[0046] Preparation method:

[0047] (1) Weigh 80% of the prescribed amount of water for injection, add the prescribed amount of mannitol, and stir to dissolve to obtain solution 1;

[0048] (2) adding a prescribed amount of sodium nitroprusside to solution 1, stirring and dissolving to obtain solution 2, and maintaining the temperature at 20° C. during the preparation process;

[0049] (3) Add an appropriate amount of citric acid to adjust the pH of solution 2 to about 5.0, add the remaining amount of water for injection to make up the volume, filter and sterilize with a 0.22 μm microporous filter membrane, and fill into brown sterile penicillin bottles at a specification of 2 mL / bottle to obtain sodium nitroprusside injection.

[0050] Comparative Example 2

[0051] Prescription (based on 1000mL): 25g sodium nitroprusside, 30g β-cyclodextrin, and appropriate amount of citric acid.

[0052] Preparation method:

[0053] (1) Weigh 80% of the prescribed amount of water for injection, add the prescribed amount of β-cyclodextrin, and stir to dissolve to obtain solution 1;

[0054] (2) adding a prescribed amount of sodium nitroprusside to solution 1, stirring and dissolving to obtain solution 2, and maintaining the temperature at 20° C. during the preparation process;

[0055] (3) Add an appropriate amount of citric acid to adjust the pH of solution 2 to about 5.0, add the remaining amount of water for injection to make up the volume, filter and sterilize with a 0.22 μm microporous filter membrane, and fill into brown sterile penicillin bottles at a specification of 2 mL / bottle to obtain sodium nitroprusside injection.

[0056] Comparative Example 3

[0057] Prescription (based on 1000mL): Sodium nitroprusside 25g, mannitol 4g, β-cyclodextrin 30g, and appropriate amount of citric acid.

[0058] Preparation method: the amount of mannitol is adjusted to 4 g, the amount of β-cyclodextrin is adjusted to 30 g, and the rest of the process is the same as Example 1.

[0059] Comparative Example 4

[0060] Prescription (based on 1000mL): Sodium nitroprusside 25g, mannitol 8g, β-cyclodextrin 20g, and appropriate amount of citric acid.

[0061] Preparation method: The amount of β-cyclodextrin is adjusted to 20 g, and the rest of the process is the same as Example 1.

[0062] Comparative Example 5

[0063] Prescription (based on 1000mL): 25g sodium nitroprusside and appropriate amount of citric acid.

[0064] Preparation method:

[0065] (1) Weigh 80% of the prescribed amount of water for injection, add the prescribed amount of sodium nitroprusside, and stir to dissolve to obtain solution 1. The temperature during the preparation process is maintained at 20° C.

[0066] (2) Add an appropriate amount of citric acid to adjust the pH of Solution 1 to about 5.0, add the remaining amount of water for injection to make up the volume, filter and sterilize with a 0.22 μm microporous filter membrane, and fill into a brown sterile penicillin bottle at a specification of 2 mL / bottle to obtain sodium nitroprusside injection.

[0067] Product quality testing methods:

[0068] 1. The content detection method of sodium nitroprusside injection described in the present invention: refer to the Chinese Pharmacopoeia 2020 edition, high performance liquid chromatography (General Rule 0512) for determination; chromatographic conditions: phenyl bonded silica gel is used as a filler, and a solution containing 0.34% tetrabutylammonium hydrogen sulfate and 0.284% anhydrous disodium hydrogen phosphate (the pH value is adjusted to 6.0 with phosphoric acid)-methanol (50:50) is used as the mobile phase; the detection wavelength is 254nm; the injection volume is 20μL.

[0069] 2. The pH detection method of the sodium nitroprusside injection described in the present invention: refer to the Chinese Pharmacopoeia 2020 edition, pH value determination method (General Rule 0631) for determination.

[0070] Test Example 1

[0071] The sodium nitroprusside injections prepared in Examples 1-5 of the present invention and Comparative Examples 1-5 were placed under an indoor light source (100-300 Lux) for 0 h, 12 h, and 24 h at room temperature of 20° C. The clarity of the injections was observed and the pH value, content, and related substances of the drug solution were detected. The results are shown in Table 1:

[0072] Table 1

[0073]

[0074]

[0075] The results in Table 1 show that the various indicators of the sodium nitroprusside injections prepared in Examples 1-5 did not change significantly within 24 hours, indicating that the injections were relatively stable under indoor light sources (100-300 Lux), especially the sodium nitroprusside injection prepared in Example 3 had better photostability.

[0076] Test Example 2

[0077] The sodium nitroprusside injection prepared in Examples 1-5 of the present invention and Comparative Examples 1-5 was placed in a light-proof, 40±2°C constant temperature box for 6 months, and samples were taken at 0, 1, 3, and 6 months to examine whether there was any precipitate. The results of 0 month were used as a benchmark to detect the content of sodium nitroferricyanide in the samples, and the residual rate (%) of the drug in 6 months was calculated. The test results are shown in Table 2:

[0078] Table 2

[0079]

[0080]

[0081] According to the results in Table 2, comparative examples 1-5 had precipitation at the bottom after being placed at 40±2°C for 6 months, while the samples of examples 1-5 remained stable after being placed at 40±2°C for 6 months, meeting the stability requirements of the injection preparation. Therefore, the sodium nitroprusside injection prepared in examples 1-5 showed excellent stability, especially the injection prepared in example 3 had better stability.

[0082] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, a person skilled in the art should understand that it is still possible to modify the technical solutions described in the aforementioned embodiments, or to perform equivalent replacements on some of the technical features therein. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A sodium nitroprusside injection, characterized in that: The invention comprises the following raw materials: sodium nitroprusside, mannitol, beta-cyclodextrin, a pH regulator and water for injection; the pH regulator makes the pH value of the injection solution be 4.5-5.

5.

2. The sodium nitroprusside injection according to claim 1, characterized in that: The pH regulator is selected from one or more of malic acid, fumaric acid, citric acid, tartaric acid, maleic acid, and succinic acid.

3. The sodium nitroprusside injection according to claim 1, characterized in that: The pH adjuster is citric acid.

4. The sodium nitroprusside injection according to claim 1, characterized in that: Each 1000 mL of the injection contains 25 g of sodium nitroprusside, 6-10 g of mannitol, and 25-45 g of β-cyclodextrin.

5. The sodium nitroprusside injection according to claim 1, characterized in that: Each 1000 mL of the injection contains 25 g of sodium nitroprusside, 8 g of mannitol, and 30 g of β-cyclodextrin.

6. A method for preparing the sodium nitroprusside injection according to any one of claims 1 to 5, characterized in that: The following steps are involved: Step 1: Weigh an appropriate amount of water for injection, add the prescribed amount of β-cyclodextrin and mannitol, and stir to dissolve to obtain solution 1; Step 2: Add the prescribed amount of sodium nitroprusside to solution 1, and stir to dissolve to obtain solution 2; Step 3: Adjust the pH value of solution 2, add the remaining amount of water for injection to make up the volume, filter and sterilize with a microporous filter membrane, and fill to obtain the finished product.

7. The preparation method according to claim 6, characterized in that: The appropriate amount of water for injection in step 1 is 70-90% of the prescribed amount, preferably 80%.

8. The preparation method according to claim 6, characterized in that: The pH in step 3 is adjusted to 4.5-5.

5.

9. The preparation method according to claim 6, characterized in that: The pore size of the microporous filter membrane in step 3 is 0.45 μm or 0.22 μm; the filling specification in step 3 is 2 mL / bottle.

10. The preparation method according to claim 6, characterized in that: During the preparation process, the temperature of the solution should be kept below 25°C.